Tyrosine kinase inhibitor sti571 in the treatment of philadelphia chromosome-positive leukemia failing myeloablative stem cell transplantation

Bone Marrow Transplantation

Volumn 30, Issue 7, 2002, Pages 453-457

  Au, W Y ^a   Lie, A K W ^a   Ma, S K ^a   Wan, T S ^a   Liang, R ^a   Chan, E C ^a   Kwong, Y L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Ph+ leukemia relapse; Stem cell transplantation; Sti571

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; HYDROXYUREA; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGRAFT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW EXAMINATION; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ISOGRAFT; MALE; PANCYTOPENIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0036775905     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703678     Document Type: Article

References (15)

1. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med 2001; 344: 1031-1037.
2. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New Engl J Med 2001; 344: 1038-1042.
3. Mughal TI, Goldman JM. Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma. Eur J Cancer 2001; 37: 561-568.
4. Baron F, Frere P, Fillet G, Beguin Y. Treatment of leukemia relapse after allogeneic hematopoietic stem cell transplantation by donor lymphocyte infusion and STI-571. Haematologica 2001; 86: 993-994.
5. Wassmann B, Klein SA, Scheuring U et al. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. Bone Marrow Transplant 2001; 28: 721-724.
6. Kwong YL, Chiu EK, Liang RH et al. Essential thrombocythemia with BCR/ABL rearrangement. Cancer Genet Cytogenet 1996; 89: 74-76.
7. Au WY, Chan AC, Lie AK et al. Isolated extramedullary relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1998; 22: 99-102.
8. Au WY, Lie AK, Ma SK et al. Therapy-related myelodysplastic syndrome of recipient origin after allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. Br J Haematol 2001; 112: 424-426.
9. O'Dwyer ME, Druker BJ. Chronic myelogenous leukaemia - new therapeutic principles. J Intern Med 2001; 250: 3-9.
10. Carella AM, Frassoni F, Negrin RS. Autografting in chronic myelogenous leukemia: new questions. Leukemia 1995; 9: 365-369. 0
11. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
12. Blau IW, Basara N, Bischoff M et al. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant. Bone Marrow Transplant 2000; 25: 41-45.
13. Olavarria E, Craddock C, Dazzi F et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002; 99: 3861-3862.
14. Dazzi F, Szydlo RM, Goldman JM. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol 1999; 27: 1477-1486.
15. Dazzi F, Szydlo RM, Craddock C et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71.